Carnosine

Phase 2Small molecule

SShahid Baba

Carnosine is one of 55 small molecule programs targeting Peripheral Arterial Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Arterial DiseaseActive, not recruiting

Peripheral Vascular DiseaseActive, not recruiting

Peripheral Arterial DiseasePhase 2

Active, not recruiting

Peripheral Vascular DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

101 competitors in Peripheral Arterial Disease

#DrugCompanyPhaseTrials

Foundayo

Eli Lilly

Phase 3

1 2

Ozempic

Novo Nordisk

Phase 3

1 3

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 4

Singulair

OOrganon and Co

Phase 3

1 5

Viagra

VViatris Specialty LLC

Phase 3

1 6

Omacor

AstraZeneca

Phase 3

1 7

Ticlid

Roche

Phase 3

1 8

Savaysa

Daiichi Sankyo

Phase 2

1 9

Kuvan

BioMarin Pharmaceutical

Phase 2

1 10

DLBS1033

DDexa Medica Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Peripheral Arterial Disease

NCT06480760

Clinical

Trials by Indication[1]

Peripheral Arterial Disease3 trials

Carnosine for Peripheral Arterial Disease

Completed·UUniversity of Louisville·Phase 2·NCT04870229·10 enrolled

Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

Recruiting·SShahid Baba·Phase 1/2·NCT06480760·144 enrolled

Carnosine for Peripheral Arterial Disease Patients

Recruiting·SShahid Baba·Phase 1/2·NCT05371145·20 enrolled

Peripheral Vascular Disease1 trial

Carnosine for Peripheral Vascular Disease

Unknown status·MMonash University·Phase 2·NCT03844113·104 enrolled

Gulf War Illness1 trial

Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

Completed·GGeorgetown University·Phase 2·NCT00810368·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Carnosine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carnosine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carnosine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shahid Baba company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShahid Baba

Carnosine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Peripheral Arterial Disease3 trials

Peripheral Vascular Disease1 trial

Gulf War Illness1 trial

References

Drug Info

Quick Facts

Related News